JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL

[Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction]

Jie Shen, Qi Zhang, Rui-Yan Zhang
Zhonghua Xin Xue Guan Bing za Zhi 2007, 35 (11): 1005-9
18269820

OBJECTIVE: This prospective study was conducted to investigate the clinical outcomes and safety of primary percutaneous coronary intervention (PCI) combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction (STEMI).

METHODS: One hundred and sixty consecutive patients with acute STEMI were randomly allocated to either primary PCI combined with tirofiban therapy (Tirofiban group, n = 80) or primary PCI treatment alone (Control group, n = 80). Baseline characteristics, PCI features and clinical outcomes during hospitalization were compared between the two groups. Left ventricular ejection fraction (LVEF) and major adverse cardiac events (MACE, including death, re-infarction and target vessel revascularization) at 30 and 180 days after discharge were also compared.

RESULTS: The baseline clinical characteristics were comparable between the two groups. Despite similar TIMI grade 3 flow (95% vs. 87.5%, P > 0.05) between the tirofiban and control groups immediately after the procedure, TMP grade 3 (75% vs. 56.3%, P < 0.05), corrected TIMI frame count (cTFC, 23.56 +/- 5.19 vs. 31.05 +/- 6.92, P < 0.01), resolution of sum of ST-segment elevation (6.51 +/- 3.56 mm vs. 4.53 +/- 2.47 mm, P < 0.01), peak value of CK-MB (225.02 +/- 105.81 microg/L vs. 269.20 +/- 110.88 microg/L, P < 0.05) and TnI (45.25 +/- 33.00 microg/L vs. 56.46 +/- 29.48 microg/L, P < 0.05) in tirofiban group were significantly superior to the control group related to a shorter hospital stay (11.38 +/- 4.63 days vs. 14.68 +/- 6.90 days, P < 0.01). Compared to control group, the MACE rates at 30 days (5.0% vs. 16.3%, P < 0.05) and 180 days (7.5% vs. 18.8%, P < 0.05) were also significantly reduced and LVEF was significantly improved (30 days: 53% +/- 7% vs. 49% +/- 9%, P < 0.01; 180 days: 59% +/- 8% vs. 53% +/- 9%, P < 0.01) in tirofiban group. Multivariate logistic analysis revealed that age > 65 years (OR = 3.42, P < 0.01), tirofiban therapy (OR = 0.56, P < 0.05) and LVEF < 0.5 during hospitalization (OR = 2.56, P < 0.01) were independent predictors of MACE rates at 180 days follow up. There was no significant difference in hemorrhagic complications between the two groups (16.3% vs. 7.5%, P > 0.05).

CONCLUSION: Adjunctive therapy with tirofiban for patients with acute STEMI who undergo primary PCI is safe and can significantly improve re-perfusion in the infarct area and clinical outcomes at 30 as well as 180 days after procedure.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
18269820
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"